Intermediatebiotechnology

Down Syndrome Genetics

Overview

Down syndrome (1/700 births) is usually trisomy 21 from meiotic nondisjunction: an extra chromosome's ~200 genes overexpressed ~1.5x, disrupting development (intellectual disability, characteristic facies, hypotonia, heart defects, Alzheimer's predisposition via APP). Risk rises with maternal age. Robertsonian 14;21 translocation causes familial cases. Screening (NIPT) and diagnostic testing guide families; research targets DYRK1A and APP pathways.

Learning objectives

  • Explain nondisjunction origin
  • Describe gene-dosage effects
  • Explain maternal-age risk
  • Distinguish trisomy, translocation, mosaic forms

The extra chromosome

95% of cases: free trisomy 21 from nondisjunction (usually maternal meiosis I). ~3-4%: Robertsonian translocation (14;21 or 21;21); ~1-2%: mosaic. Chromosome 21 is small (~200-300 genes) but dosage-sensitive: 1.5x expression of DYRK1A, APP, SOD1 and others perturbs neurodevelopment.

Dosage, not mutation

No gene is broken; too much normal product disrupts development: the dosage hypothesis.

Phenotype

Intellectual disability (variable, usually mild-moderate), characteristic facial features, hypotonia, single palmar crease; congenital heart defects (~50%), GI atresias, leukemia risk elevated, and near-universal Alzheimer's pathology by 40 (APP triplication -> amyloid). Life expectancy now ~60.

APP and Alzheimer's

Three APP copies guarantee amyloid pathology: Down syndrome illuminates Alzheimer's mechanisms.

Maternal age and recurrence

Risk: ~1/1500 at 20, ~1/100 at 40, ~1/30 at 45 (aging oocytes missegregate). Free trisomy recurrence ~1% (+ age risk). Translocation carriers: 14;21 carrier mother ~10-15%, father ~1-3%; 21;21 carriers have 100% recurrence: karyotype parents after any translocation case.

Karyotype translocation cases

Finding a translocation changes everything: parental testing determines recurrence (up to 100%).

Screening and support

First-trimester combined screen, NIPT (cell-free DNA, >99% sensitive for T21), diagnostic amnio/CVS. Management: cardiac repair, thyroid/leukemia surveillance, early intervention, inclusive education. Research: DYRK1A inhibitors, anti-amyloid strategies for DS Alzheimer's.

Screening informs, families decide

Testing provides information; decisions belong to families with non-directive counseling.

Key points

  • Usually free trisomy 21 from maternal nondisjunction
  • 1.5x dosage of ~200 genes disrupts development
  • Risk rises steeply with maternal age
  • Translocation/mosaic forms differ in recurrence; NIPT screens, amnio diagnoses

Common misconceptions

✗ Myth: Down syndrome is inherited.

✓ Truth: Usually sporadic nondisjunction; only translocation forms (3-4%) are inherited.

✗ Myth: All individuals are severely affected.

✓ Truth: Abilities vary widely; many live semi-independently, work, and participate fully in communities.

Practice questions

Q1. Most Down syndrome is caused by
  1. A point mutation
  2. Meiotic nondisjunction giving trisomy 21
  3. A virus
  4. Imprinting
Answer: B.

~95% free trisomy, usually maternal meiosis I error.

Q2. A 21;21 Robertsonian carrier has recurrence risk of
  1. 1%
  2. 10%
  3. ~100%
  4. 0%
Answer: C.

Every gamete gets the translocation chromosome: all children have Down syndrome.

Q3. The Alzheimer's link in Down syndrome involves
  1. APP triplication
  2. Tau deletion
  3. ApoE loss
  4. Nothing
Answer: A.

Three APP copies drive amyloid overproduction.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why does maternal age matter?

Oocytes arrested in meiosis I for decades accumulate segregation errors: cohesin loss with age.

What is mosaic Down syndrome?

Mitotic nondisjunction after fertilization: mixed trisomic/normal cells, often milder phenotype.

Why study APP in Down syndrome?

Triplicated APP drives early Alzheimer's: DS is a genetic model of amyloid pathogenesis.